Becton Dickinson Current Ratio 2010-2024 | BDX
Current and historical current ratio for Becton Dickinson (BDX) from 2010 to 2024. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations. Becton Dickinson current ratio for the three months ending September 30, 2024 was .
| Becton Dickinson Current Ratio Historical Data |
| Date |
Current Assets |
Current Liabilities |
Current Ratio |
| 2024-09-30 |
$10.47B |
$8.95B |
1.17 |
| 2024-06-30 |
$12.21B |
$6.61B |
1.85 |
| 2024-03-31 |
$10.34B |
$7.33B |
1.41 |
| 2023-12-31 |
$8.16B |
$7.54B |
1.08 |
| 2023-09-30 |
$8.68B |
$6.64B |
1.31 |
| 2023-06-30 |
$8.59B |
$6.88B |
1.25 |
| 2023-03-31 |
$9.59B |
$7.30B |
1.31 |
| 2022-12-31 |
$8.18B |
$7.63B |
1.07 |
| 2022-09-30 |
$8.14B |
$7.81B |
1.04 |
| 2022-06-30 |
$9.55B |
$7.08B |
1.35 |
| 2022-03-31 |
$10.15B |
$6.66B |
1.53 |
| 2021-12-31 |
$8.31B |
$6.74B |
1.23 |
| 2021-09-30 |
$8.84B |
$6.63B |
1.33 |
| 2021-06-30 |
$9.54B |
$7.75B |
1.23 |
| 2021-03-31 |
$10.00B |
$5.38B |
1.86 |
| 2020-12-31 |
$9.54B |
$7.02B |
1.36 |
| 2020-09-30 |
$8.97B |
$5.84B |
1.54 |
| 2020-06-30 |
$8.83B |
$6.07B |
1.46 |
| 2020-03-31 |
$8.56B |
$8.76B |
0.98 |
| 2019-12-31 |
$6.44B |
$6.73B |
0.96 |
| 2019-09-30 |
$6.66B |
$5.66B |
1.18 |
| 2019-06-30 |
$6.78B |
$6.24B |
1.09 |
| 2019-03-31 |
$6.84B |
$7.11B |
0.96 |
| 2018-12-31 |
$6.94B |
$7.15B |
0.97 |
| 2018-09-30 |
$7.41B |
$7.22B |
1.03 |
| 2018-06-30 |
$7.53B |
$6.11B |
1.23 |
| 2018-03-31 |
$7.51B |
$4.43B |
1.70 |
| 2017-12-31 |
$7.54B |
$4.90B |
1.54 |
| 2017-09-30 |
$18.63B |
$3.34B |
5.58 |
| 2017-06-30 |
$18.21B |
$3.27B |
5.56 |
| 2017-03-31 |
$4.89B |
$4.02B |
1.22 |
| 2016-12-31 |
$5.19B |
$4.57B |
1.14 |
| 2016-09-30 |
$6.37B |
$4.40B |
1.45 |
| 2016-06-30 |
$6.53B |
$4.22B |
1.55 |
| 2016-03-31 |
$6.61B |
$4.38B |
1.51 |
| 2015-12-31 |
$5.64B |
$4.53B |
1.25 |
| 2015-09-30 |
$5.66B |
$4.38B |
1.29 |
| 2015-06-30 |
$6.30B |
$4.52B |
1.40 |
| 2015-03-31 |
$7.00B |
$4.50B |
1.56 |
| 2014-12-31 |
$12.11B |
$2.08B |
5.82 |
| 2014-09-30 |
$6.13B |
$2.24B |
2.74 |
| 2014-06-30 |
$6.05B |
$2.09B |
2.89 |
| 2014-03-31 |
$5.95B |
$2.02B |
2.95 |
| 2013-12-31 |
$5.74B |
$2.00B |
2.88 |
| 2013-09-30 |
$5.87B |
$2.13B |
2.76 |
| 2013-06-30 |
$5.44B |
$1.69B |
3.21 |
| 2013-03-31 |
$5.50B |
$1.88B |
2.93 |
| 2012-12-31 |
$5.48B |
$2.00B |
2.73 |
| 2012-09-30 |
$5.32B |
$1.98B |
2.69 |
| 2012-06-30 |
$5.29B |
$1.89B |
2.80 |
| 2012-03-31 |
$5.30B |
$1.62B |
3.27 |
| 2011-12-31 |
$5.69B |
$1.61B |
3.55 |
| 2011-09-30 |
$4.67B |
$1.82B |
2.56 |
| 2011-06-30 |
$5.07B |
$1.66B |
3.06 |
| 2011-03-31 |
$4.86B |
$1.58B |
3.08 |
| 2010-12-31 |
$4.95B |
$1.61B |
3.07 |
| 2010-09-30 |
$4.51B |
$1.67B |
2.70 |
| 2010-06-30 |
$4.12B |
$1.53B |
2.69 |
| 2010-03-31 |
$3.94B |
$1.47B |
2.69 |
| 2009-12-31 |
$4.06B |
$1.54B |
2.64 |
| 2009-09-30 |
$4.65B |
$1.78B |
2.62 |
| 2009-06-30 |
$4.49B |
$1.65B |
2.73 |
| 2009-03-31 |
$3.41B |
$1.51B |
2.26 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical & Dental Supplies |
$64.745B |
$20.178B |
|
Becton, Dickinson and Company, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. BD's operations consisted of three business segments: BD Medical, BD Diagnostics and BD Biosciences. The company's organizational structure was realigned to form two principal business segments: BD Medical, BD Life Sciences and BD Interventional. BD Medical: BD Medical's major product lines include needles, syringes and intravenous catheters for medication delivery and generic prefilled injectables. BD Life Sciences - BD Diagnostics provides products for the safe collection and transport of diagnostics specimens to detect a broad range of infectious diseases, healthcare-associated infections and cancer. BD Biosciences produces research and clinical tools that facilitate the study of cells to gain a better understanding of normal and disease processes. With the acquisition of C.R. Bard, BD added a new segment - BD Interventional.
|
